Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Journal of Cancer Research and Clinical Oncology
Erschienen in: Journal of Cancer Research and Clinical Oncology 7/2012

01.07.2012 | Original Paper

Effect of shRNA targeting survivin on ovarian cancer

verfasst von: Jun Xing, Chang-Ru Jia, Yan Wang, Jing Guo, Yan Cai

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 7/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study investigated the effect of shRNA targeting survivin on cultured ovarian cancer cells and on a murine ovarian cancer xenograft.

Methods

An RNAi plasmid for survivin was transfected into SKOV3 cells, and the effect of shRNA targeting survivin on the expression of survivin was determined. Transmission electron microscopy (TEM), flow cytometry, and TUNEL staining were used to assess apoptosis. The MTT assay was used to measure cell growth and changes in cisplatin sensitivity. SKOV3 cells were injected into nude mice, and the effect of shRNA targeting the survivin gene on tumor growth was assessed.

Results

SKOV3 cells transfected with an RNAi plasmid against survivin had increased apoptosis and slower growth. At the molecular level, these cells also had lower expression of survivin. Nude mice inoculated with SKOV3 cells developed cancers, and treatment with shRNA targeting survivin markedly inhibited the growth of these cancers with no obvious side effects.

Conclusions

Our studies of SKOV3 cells and ovarian cancer xenografts in nude mice indicate that shRNA targeting survivin has potential for the treatment of ovarian cancer.
Literatur
Altieri DC (2010) Survivin and IAP proteins in cell-death mechanisms. Biochem J 430:199–205PubMedCrossRef
Anne TM, Taina TH (2010) Levels of Circulating TIMP-2 and MMP2-TIMP2 Complex Are Decreased in Squamous Cervical Carcinoma. Obstet Gynecol Int. doi:10.​1155/​2010/​179351
Deng KX, Zhong L, Jiang MX, Wang PL, Chen Y (2005a) RNA interference silencing expression of survivin gene and reversing drug resistance of ovarian cancer cell line SKOV3/ADM. Zhonghua Fu Chan Ke Za Zhi 40:836–839 [Chinese]PubMed
Deng KX, Zhong L, Jiang MX, Chen WX, Chen Y, He H (2005b) Effect of RNAi-mediated survivin gene silencing on apoptosis of ovarian cancer cell lines SKOV3 and SKOV3/ADM. Ai Zheng 24:945–950 [Chinese]PubMed
Dutta A, Sen T, Banerji A, Das S, Chatterjee A (2009) Studies on multifunctional effect of all-trans retinoic acid (ATRA) on matrix metalloproteinase-2 (MMP-2) and its regulatory molecules in human breast cancer cells (MCF-7). J Oncol. doi:10.​1155/​2009/​627840
Gong YI, Xu GM, Huang WD (2000) Expression of matrix metalloproteinases and the tissue inhibitors of metalloproteinases and their local invasiveness and metastasis in Chinese human pancreatic cancer. J Surg Oncol 73:95–99PubMedCrossRef
Hanemaaier R, Verheijen JH, Mayuire TM, Visser H, Toet K, McDermott E, O’Higgins N, Duffy MJ (2000) Increased gelatinase-A and gelatinase-B activities in malignant vs benign breast tumors. Int J Cancer 86:204–207CrossRef
Ikeguchi M, Kaibara N (2001) Changes in survivin messenger RNA level during cisplatin treatment in gastric cancer. Int J Mol Med 8:661–666PubMed
Ikeguchi M, Liu J, Kaibara N (2002) Expression of surviving mRNA and protein in gastric cancer cell line (MKN-45) during cisplatin treatment. Apoptosis 7:23–29PubMedCrossRef
Jiang X, Wilford C, Duensing S, Munger K, Jones G, Jones D (2001) Participation of Survivin in mitotic and apoptotic activities of normal and tumor-derived cells. J Cell Biochem 83:342–354PubMedCrossRef
Johnson AL, Langer JS, Bridgham JT (2002) Survivin as a cell cycle-related and antiapoptotic protein in granulosa cells. Endocrinology 143:3405–3413PubMedCrossRef
Kahari VM, Saarialho-Kere U (1999) Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 31:34–45PubMedCrossRef
Li G, Xie B, Li X, Chen Y, Wang Q, Xu Y, Xu-Welliver M, Zou L (2012) Down-regulation of survivin and Hypoxia-Inducible Factor-1α by β-elemene enhances the radiosensitivity of lung adenocarcinoma xenograft. Cancer Biother Radiopharm. [PMID: 22248028, Epub ahead of print]
Liu Q, Fu H, Xing R, Tie Y, Zhu J, Sun Z, Zheng X (2008) Survivin knockdown combined with apoptin overexpression inhibits cell growth significantly. Cancer Biol Ther 7:1053–1060PubMedCrossRef
Lukaszewicz-Zajac M, Mroczko B, Szmitkowski M (2009) The significance of metalloproteinases and their inhibitors in gastric cancer. Postepy Hig Med Dosw 63:258–265
McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 334:1–6PubMedCrossRef
Mroczko B, Groblewska M, Okulczyk B, Kedra B, Szmitkowski M (2010) The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients. Int J Colorectal Dis 25:1177–1184PubMedCrossRef
Muller D, Quantin B, Gesnel MC, Millon-Collard R, Abecassis J, Breathnach R (1994) The collagenase gene family in humans consists of at least four members. Biochem J 253:187–192
Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) Matrix metalloproteinase: biologic activity and clinical implication. J Clin Oncol 18:1135–11491PubMed
Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK (2011) RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 11:59–67PubMedCrossRef
Posadas EM, Davidson B, Kohn EC (2004) Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review the recent literature. Curr Opin Oncol 16:478–484PubMedCrossRef
Shen J, Liu J, Long Y, Miao Y, Su M, Zhang Q, Han H, Hao X (2009) Knockdown of survivin expression by siRNAs enhances chemosensitivity of prostate cancer cells and attenuates its tumorigenicity. Acta Biochim Biophys Sin (Shanghai) 41:223–230CrossRef
Vivas-Mejia PE, Rodriguez-Aguayo C, Han HD, Shahzad MM, Valiyeva F, Shibayama M, Chavez-Reyes A, Sood AK, Lopez-Berestein G (2011) Silencing survivin splice variant 2B leads to antitumor activity in taxane–resistant ovarian cancer. Clin Cancer Res 17:3716–3726PubMedCrossRef
Vu TH, Werb Z (2000) Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 14:2123–2133PubMedCrossRef
Yamamoto H, Ngan CY, Monden M (2008) Cancer cells survive with survivin. Cancer Sci 99:1709–1714PubMedCrossRef
Ye S, Humphries S, Henney A (1998) Matrix metalloproteinases: implication in vascular matrix remodelling during atherogenesis. Clin Sci 94:103–110PubMed
Zhang X, Li N, Wang YH, Huang Y, Xu NZ, Wu LY (2009) Effects of survivin siRNA on growth, apoptosis and chemosensitivity of ovarian cancer cells SKOV3/DDP. Zhonghua Zhong Liu Za Zhi 31:174–177 [Chinese]PubMed
Zhen HN, Li LW, Zhang W, Fei Z, Shi CH, Yang TT, Bai WT, Zhang X (2007) Short hairpin RNA targeting survivin inhibits growth and angiogenesis of glioma U251 cells. Int J Oncol 31:1111–1117PubMed
Zhou J, Gan N, Zhang W, Lu W, Xie X (2010) Proliferation suppression and apoptosis of ovarian carcinoma cells induced by small interfering RNA against vascular endothelial growth factor. J Obstet Gynaecol Res 36:232–238PubMedCrossRef
Metadaten
Titel
Effect of shRNA targeting survivin on ovarian cancer
verfasst von
Jun Xing
Chang-Ru Jia
Yan Wang
Jing Guo
Yan Cai
Publikationsdatum
01.07.2012
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 7/2012
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-012-1196-0

Weitere Artikel der Ausgabe 7/2012

Journal of Cancer Research and Clinical Oncology 7/2012 Zur Ausgabe

Original Paper

Basaloid squamous cell carcinoma of the esophagus

Original Paper

Pretreatment with AT-101 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of breast cancer cells by inducing death receptors 4 and 5 protein levels

Original Paper

Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer

Original Paper

Fludarabine combined with radiotherapy in patients with locally advanced NSCLC lung carcinoma: a phase I study

Original Paper

Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) staging

Original Paper

Nanog and Oct4 overexpression increases motility and transmigration of melanoma cells

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise